Rhabdomyosarcoma - Pipeline Review, H2 2020

September 2020 | 524 pages | ID: RAD03FA0D01EN
Global Markets Direct

Abstracts

Rhabdomyosarcoma - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2020, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.
Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 19, 9, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1 and 2 molecules, respectively.
Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Rhabdomyosarcoma - Overview
Rhabdomyosarcoma - Therapeutics Development
Rhabdomyosarcoma - Therapeutics Assessment
Rhabdomyosarcoma - Companies Involved in Therapeutics Development
Rhabdomyosarcoma - Drug Profiles
Rhabdomyosarcoma - Dormant Projects
Rhabdomyosarcoma - Discontinued Products
Rhabdomyosarcoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Rhabdomyosarcoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Rhabdomyosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2020
Rhabdomyosarcoma - Pipeline by Alxerion Biotech Corp, H2 2020
Rhabdomyosarcoma - Pipeline by Amgen Inc, H2 2020
Rhabdomyosarcoma - Pipeline by Arisaph Pharmaceuticals Inc, H2 2020
Rhabdomyosarcoma - Pipeline by Bayer AG, H2 2020
Rhabdomyosarcoma - Pipeline by Biogenera SpA, H2 2020
Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Rhabdomyosarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2020
Rhabdomyosarcoma - Pipeline by Cellectar Biosciences Inc, H2 2020
Rhabdomyosarcoma - Pipeline by Cellestia Biotech AG, H2 2020
Rhabdomyosarcoma - Pipeline by Eisai Co Ltd, H2 2020
Rhabdomyosarcoma - Pipeline by Epizyme Inc, H2 2020
Rhabdomyosarcoma - Pipeline by Exelixis Inc, H2 2020
Rhabdomyosarcoma - Dormant Projects, H2 2020
Rhabdomyosarcoma - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Rhabdomyosarcoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Advenchen Laboratories LLC
Alxerion Biotech Corp
Amgen Inc
Arisaph Pharmaceuticals Inc
Bayer AG
Biogenera SpA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cellectar Biosciences Inc
Cellestia Biotech AG
Eisai Co Ltd
Epizyme Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Galapagos NV
GlaxoSmithKline Plc
ImmunityBio Inc
Iproteos SL
Ipsen SA
MacroGenics Inc
Mana Therapeutics Inc
Mirati Therapeutics Inc
NanoRED Biotechnology
NantKwest Inc
Novartis AG
Ohara Pharmaceutical Co Ltd
Oncoheroes Biosciences Inc
Oncolys BioPharma Inc
PEEL Therapeutics Inc
Pfizer Inc
Provectus Biopharmaceuticals Inc
Seneca Therapeutics Inc
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Taiwan Liposome Co Ltd
Tarveda Therapeutics Inc
Veana Therapeutics LLC